Introduction: Virus-like particles (VLP) extracted from medicinal plant products are used and applied for the development of recombinant vector vaccines against various infectious diseases. This vaccine is mainly used for stimulating protective and longlasting immune responses. In general, these vaccines mainly target the antigen-presenting cells (APC) or dendritic cells which may induce both humoral and cellular immune response. VLP based vaccines have been used so far in drug delivery, genetic therapy, cellular targeting, cancer treatment, therapeutic vaccine, etc. Aim and Objective: This paper mainly reviews the existing developmental efforts through researchers to improve the production of plant virus particles based vaccines. Results: However, the antigenicity and immunogenicity of such vaccines have various limitations varying from the length of the peptide that can be expressed on the surface to the duration of immunogenicity developed in the host. In other words, plant virus-like particles may provide some many benefits to the vaccine industry but still showed some challenges that limit the production of vaccines. Various efforts were taken or still ongoing about producing an efficient vaccine for human and veterinary related diseases. Conclusion: Recently, plant virus-like particles are used for the development of vaccine platforms and have been tested in human and veterinary studies, suggesting that plant virus-based vaccines will be introduced into clinical and veterinary practice shortly.